Pharma major Lupin Ltd on Wednesday posted a profit of Rs 858.86 crore for the fiscal third quarter, reporting a growth of 38.82 per cent in comparison to Rs 618.70 crore recorded during the corresponding quarter of FY24. It recorded revenue from operations at Rs 5767.71 crore, up 10.97 per cent on-year. Revenue during the third quarter of FY24 was at Rs 5197.41 crore. The company EBITDA stood at Rs 1409.60 crore.
The company maintained that the employee benefits cost was 17.5 per cent of sales at Rs 984.40 crore as compared to Rs 889.20 crore in Q3FY24. Manufacturing and other expenses were at 30.2 per cent of sales at Rs 1695.90 crore.
ALSO READRashmi Saluja moves court again, Religare board fights back
Nilesh Gupta, Managing Director, Lupin Limited, said, “Our third-quarter results highlight our continued strength, with both revenue and EBITDA showing sustained growth. US revenues led by building scale in new products have been pivotal for our growth, supported by a strong nine-month performance from our India and EMEA regions. We look forward to maintaining this momentum in the ensuing quarters backed by growth in sales, commercial and operating efficiencies, and strong compliance.”
Also Read Q3 Results 2025: LIC profit rises by 16.26%; M&M profit up 19.64% Calvin Klein, Tommy Hilfiger retailer Arvind Fashions’ Q3 profit rises by 58.20% to Rs 47.65 cr L&T Q3 Results: Profit rises by 13.96% to Rs 3,358.84 crore, revenue up 17.31% on strong order book of over Rs 1 lakh crore ICICI Bank’s Q3 profit rises by 14.81% YoY to Rs 11,792.42 crore, NII at Rs 20,370.6 crore
Shares of Lupin went down by 0.31 per cent at 11:30 am to a trading price of Rs 2,059.95.
Lupin’s balance sheet
Lupin recorded Operating working capital as on December 31, 2024 at Rs 7070.00 crore. Capital expenditure for the quarter stood at Rs 124.10 crore and net debt came in at Rs 102.70 crore.
R&D investment
The pharma major posted investment in R&D at Rs 434.40 crore during the quarter in review, which is 7.7 per cent of sales. Lupin received approval for 6 ANDA from the US FDA in the quarter. Cumulative ANDA filings with the US FDA stand at 430 as of December 31,
» Read More
